We observed for the first time that UCB35625 (CCR1/CCR3 antagonist) inhibits pain-like behavior, without influencing the motor dysfunction observed in neuropathy, which confirms its analgesic effectiveness. This evidence concerns the gene CCR3 and neuropathy.